Anti-CD3 recombinant diphtheria immunotoxin therapy of cutaneous T cell lymphoma

A. E. Frankel, S. L. Zuckero, A. A. Mankin, M. Grable, K. Mitchell, Y. J. Lee, D. M. Neville, J. H. Woo

Research output: Contribution to journalReview article

41 Scopus citations

Abstract

The recombinant CD3 immunotoxin, A-dmDT390-bisFv(UCHT1), composed of the catalytic and translocation domains of diphtheria toxin fused to two single chain Fv fragments of an anti-CD3ε monoclonal antibody was administered to five patients with cutaneous T cell lymphoma (CTCL) by eight 15 min intravenous infusions over four days. Side effects were fever, chills, nausea, hypoalbuminemia, transaminasemia and reactivation of EBV and CMV. Half-life of drug was 40 min. Anti-immunotoxin antibodies developed in all patients after two weeks. Two patients had partial remissions lasting 1 and 6+ months. The agent is undergoing further dose escalation and shows promising results in this disease.

Original languageEnglish (US)
Pages (from-to)104-109
Number of pages6
JournalCurrent Drug Targets
Volume10
Issue number2
DOIs
StatePublished - May 18 2009

Keywords

  • Cutaneous T cell lymphoma
  • Diphtheria toxin
  • Immunotoxin

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Fingerprint Dive into the research topics of 'Anti-CD3 recombinant diphtheria immunotoxin therapy of cutaneous T cell lymphoma'. Together they form a unique fingerprint.

  • Cite this

    Frankel, A. E., Zuckero, S. L., Mankin, A. A., Grable, M., Mitchell, K., Lee, Y. J., Neville, D. M., & Woo, J. H. (2009). Anti-CD3 recombinant diphtheria immunotoxin therapy of cutaneous T cell lymphoma. Current Drug Targets, 10(2), 104-109. https://doi.org/10.2174/138945009787354539